Valuation dashboard for Caris Life Sciences, Inc. (CAI) with P/E 76.10, P/B 13.53, EV/EBITDA 48.37 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms.
Analysis Summary
Caris Life Sciences, Inc. reported revenue of $812.0M in the most recent fiscal year, growing at a 5-year CAGR of 14.3%.
Trailing-twelve-month margins: gross margin 69.7%, operating margin 15.5%, net margin 10.6%.
At the current price of $30.39, CAI trades at a P/E of 76.10 and an ROE of 18.77%. Market capitalisation stands at $8.6B.
Balance sheet quality for CAI: current ratio of 7.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 76.10 |
| Price / Book | 13.53 |
| EV / EBITDA | 48.37 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-87.76 |
| vs Current Price | -388.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CAI | Caris Life Sciences, Inc. | $8.6B | 76.10 | 13.53 | 18.8% |
| MRNA | Moderna, Inc. | $75.4B | 11.13 | -39.2% | |
| JAZZ | Jazz Pharmaceuticals plc | $14.9B | 15.50 | 3.10 | -8.2% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $11.8B | 27.79 | -56.6% | |
| ABVX | Abivax S.A. | $6.8B | 18.05 | -85.9% | |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 31.21 | 89.76 | 180.6% |
| CYTK | Cytokinetics, Incorporated | $8.2B | 164.0% | ||
| CORT | Corcept Therapeutics Incorporated | $12.6B | 223.52 | 17.35 | 8.4% |
Price
| Price | $30.39 |
| Market Cap | $8.6B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 18.77% |
| Return on Invested Capital | 14.67% |
| Return on Assets | 8.55% |
| Gross Margin | 69.66% |
| Operating Margin | 15.49% |
| Net Margin | 10.62% |
Related companies: ABVX · CORT · CYTK · HALO · JAZZ · MDGL · MRNA
Explore sector: Healthcare · Biotechnology
More sections of CAI: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks